Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nonsteroidal antiinflammatory agents.

J H Botting

    Drugs of Today (Barcelona, Spain : 1998)
    |September 16, 2003
    PubMed
    Summary
    This summary is machine-generated.

    Selective nonsteroidal anti-inflammatory drugs (NSAIDs) targeting cyclooxygenase-2 (COX-2) offer anti-inflammatory benefits with fewer side effects than traditional NSAIDs. Research focuses on developing potent COX-2 inhibitors for conditions like arthritis and potentially cancer.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Animal research. Various fallacies persist in vivisection debate.

    BMJ (Clinical research ed.)·2001
    Same author

    Animal research is vital to medicine.

    Scientific American·1997
    Same author

    Animal rights and wrongs.

    Nature medicine·1995
    Same author

    Relationship between gender difference in intravascular aggregation of platelets and the fibrinolytic pathway in the rat.

    Archives internationales de pharmacodynamie et de therapie·1991
    Same author

    Adrenaline inhibits adenosine diphosphate induced intravascular aggregation of rat platelets through stimulation of alpha 2 adrenoceptors.

    Cardiovascular research·1991
    Same author

    Pharmacodynamic interaction between oestradiol and adrenaline on intravascular aggregation induced by adenosine diphosphate in the rat.

    Archives internationales de pharmacodynamie et de therapie·1990

    Area of Science:

    • Pharmacology
    • Medicinal Chemistry
    • Gastroenterology
    • Nephrology

    Background:

    • Nonsteroidal anti-inflammatory drugs (NSAIDs) have been primary treatments for rheumatoid arthritis since aspirin's synthesis in 1897.
    • NSAIDs share therapeutic effects (antipyretic, analgesic, anti-inflammatory) and toxicities (gastric, renal).
    • Vane's 1971 discovery linked NSAID actions to cyclooxygenase (COX) inhibition.

    Purpose of the Study:

    • To explain differential NSAID toxicity despite similar COX inhibition.
    • To explore the development of NSAIDs with improved safety profiles.
    • To investigate potential new applications for selective COX-2 inhibitors.

    Main Methods:

    • Discovery of two COX isoforms: COX-1 (constitutive, physiological) and COX-2 (inducible, inflammation-related).

    Related Experiment Videos

  • Structural modification of NSAIDs to enhance selectivity for COX-2.
  • Elucidation of the crystal structures of both COX-1 and COX-2 enzymes.

    • Main Results:

    • Development of NSAIDs highly selective for COX-2, offering anti-inflammatory effects without typical NSAID side effects.
    • Expanded understanding of prostanoid roles in pathophysiology.
    • Identification of potential new therapeutic uses for selective COX-2 inhibitors.

    Conclusions:

    • Selective COX-2 inhibitors represent a significant advancement over traditional NSAIDs, potentially reducing gastrointestinal and renal toxicity.
    • Further research and clinical trials are necessary to confirm the long-term safety and efficacy of potent, selective COX-2 inhibitors.
    • Selective COX-2 inhibition opens avenues for treating conditions beyond inflammation, including certain cancers and neurodegenerative diseases.